Syndax Pharmaceuticals, Inc. - Common Stock (SNDX)
14.65
0.00 (0.00%)
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment
The company is dedicated to discovering and advancing novel drugs that aim to enhance patient outcomes by targeting specific mechanisms of cancer progression, particularly through immuno-oncology and epigenetic modulation. Syndax is actively engaged in multiple clinical trials to evaluate the efficacy and safety of its product candidates, which are designed to leverage the body's immune system and improve therapeutic responses in various malignancies. By fostering collaborations and pursuing a strategic pipeline, Syndax seeks to provide new options for patients battling cancer.
Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key milestones expected in 2024 and 2025.
The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious post-transplant condition.
Syndax Pharmaceuticals Inc (NASDAQSNDX) shares are trading higher after the company shared data from multiple trials of revumenib in combination with standard-of-care agents in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2r) relapsed/refractory
Companies Reporting Before The Bell • AudioCodes (NASDAQAUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Syndax Pharmaceuticals Inc (NASDAQSNDX) announced topline data from the AUGMENT-101 trial of revumenib in adult and pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and
Gainers AERWINS Technologies Inc. (NASDAQAWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not limited to possible sale/other disposition of assets.
